According to a 2014 survey by the American Society for Dermatologic Surgery, approximately seven out of 10 consumers are bothered by submental fullness (also known as a double chin). Submental fullness is a common yet undertreated condition that can detract from an otherwise balanced and harmonious facial appearance – leading to an older and heavier look. Submental fullness can affect both women and men of all ages and weight, and it is often resistant to diet and exercise and can be influenced by multiple factors including aging and genetics.

The FDA recently approved the first and only non-surgical treatment for reduction of submental fullness called Kybella (formerly known as ATX-101). It has been under development for more than nine years, and it is the subject of over 20 clinical studies involving more than 2,600 patients. Dr. Lupo was one of the investigators during the clinical trial, and she has been named a trainer for Kythera, the makers of Kybella.

Kybella is a non-human and non-animal patented formulation of deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected into subcutaneous fat, Kybella causes the destruction of fat cells, followed by a natural healing and elimination process to improve the chin profile. Once destroyed, those cells cannot store or accumulate fat. Patients who want to dramatically improve their jawline with non-surgical options can be treated with Kybella in conjunction with dermal fillers and/or radio-frequency and ultrasound devices for additional definition and skin tightening.

Kybella is administered by injections into the fat under the chin through a series of treatments spaced no less than one month apart. Many patients experienced visible results in two to four treatments, and up to six treatments may be administered depending on the desired outcome of the patient and treating physician. Once the aesthetic response is achieved, retreatment is not expected.

The Lupo Center for Aesthetic and General Dermatology will begin treating patients with Kybella in late June.  If you are interested in learning more about this treatment or to see if you are a candidate, please contact our office to schedule a consultation.